Join the Acute Lymphoblastic Leukemia group to help and get support from people like you.
Acute Lymphoblastic Leukemia News
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
MONDAY, March 10, 2025 – For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers...
Neurocognitive Battery Feasible in 3-Year-Olds During Leukemia Treatment
WEDNESDAY, Dec. 18, 2024 – A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to a study published online Dec. 9 in Pediatric...
ASH: Blinatumomab + Chemo Aids Survival in B-Cell Acute Lymphoblastic Leukemia
THURSDAY, Dec. 12, 2024 – For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for relapse, adding blinatumomab to combination...
Durable Response High With Obe-Cel in B-Cell Acute Lymphoblastic Leukemia
WEDNESDAY, Dec. 11, 2024 – For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen ...
Newly Approved Aucatzyl Provides New Hope Against a Tough-to-Treat Leukemia in Adults
TUESDAY, Dec. 3, 2024 – A newly approved immunotherapy can help adults with a difficult-to-treat form of leukemia, clinical trial results show. Aucatzyl (obecabtagene autoleucel) worked on more than...
FDA Approves Imkeldi (imatinib) Oral Solution for the Treatment of Certain Forms of Leukemia and Other Cancers
CAMBRIDGE, Mass.-- November 25, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved Imkeldi (imatinib) oral solution, the fir...
FDA Approves Revuforj (revumenib) for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ – Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) as the first and...
FDA Approves Aucatzyl (obecabtagene autoleucel) for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) – Autolus Therapeutics plc (Nasdaq: AUTL), an early-commercial stage biopharmaceutical company developing next-generation programmed T cell therapies, today ...
Shorla Oncology Announces U.S. FDA Expanded Approval of Jylamvo (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications
CAMBRIDGE, Mass.--(BUSINESS WIRE) October 29, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has e...
Measurable Residual Disease Results After Consolidation Therapy Predictive of Relapse in Pediatric Leukemia
TUESDAY, Sept. 24, 2024 – For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC) can be used to predict the need for...
Genetic Subtype, Genomic Alterations Linked to Relapse in Leukemia
THURSDAY, Aug. 22, 2024 – Genetic subtype, aneuploidy patterns, and genomic alterations are associated with the risk for relapse in childhood acute lymphoblastic leukemia (ALL), according to a study...
Blinatumomab + Chemo Ups Survival in B-Cell Precursor Acute Lymphoblastic Leukemia
MONDAY, July 29, 2024 – For adult patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) who have measurable residual disease (MRD)-negative remission, blinatumomab in addition to...
Ophthalmologic Manifestations of Acute Leukemia Are Heterogeneous
WEDNESDAY, July 17, 2024 – Ophthalmologic manifestations of acute leukemia are heterogeneous and detectable at initial presentation or relapse, according to a study published online July 10 in the...
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for Iclusig (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
OSAKA, Japan and CAMBRIDGE, Massachusetts, March 19, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug A...
FDA Approves Besponsa (inotuzumab ozogamicin) for Pediatric Patients with Acute Lymphoblastic Leukemia
On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor...